Drug Profile
Anti-Rev monoclonal antibody gene therapy
Latest Information Update: 02 Sep 1998
Price :
$50
*
At a glance
- Originator Thomas Jefferson University
- Class Antivirals; Gene therapies; Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 02 Sep 1998 No-Development-Reported for HIV infections treatment in USA (Unknown route)
- 28 Mar 1995 Preclinical development for HIV infections treatment in USA (Unknown route)